Just a new in vivo study I thought some might find interesting.
AAPS J. 2013 Apr 17. [Epub ahead of print]
Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice.
Gao M, Liu D.
Source
Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, 450 Pharmacy South, 250 West Green Street, Athens, Georgia, 30602, USA.
Abstract
Liver X receptor (LXR) has been identified as a potential target for treatment of atherosclerosis and diabetes. Activation of LXR, however, is associated with increased lipogenesis and fat accumulation in the liver. The objective of the current study was to examine the effect of resveratrol on LXR activator-induced fat accumulation in liver using mice as an animal model. Three groups of C57BL/6 mice were studied. Animals in group 1 were treated with T0901317, a potent activator of LXR in mice. Animals in group 2 served as the control and were treated with carrier solution and those in group 3 were treated with T0901317/resveratrol combination. Using histochemical and biochemical methods, we demonstrate that resveratrol treatment significantly suppressed fat accumulation in the liver induced by T0901317. In addition, resveratrol completely blocked elevation of blood levels of triglyceride and cholesterol and reduced blood glucose level. Quantitative PCR analysis revealed that resveratrol treatment did not change the mRNA levels of abca1, abcg1, cyp7a1, srebp-1c, chrebp, and acc genes compared to that of animals treated with T0901317 alone but reduced pepck and g6p gene expressions. Immunohistochemistry and Western blot analyses show resveratrol treatment activated AMP-activated protein kinase (AMPK) and increased phosphorylation of acetyl-CoA carboxylase. Treatment with T0901317 on hepatocytes increased intracellular fat accumulation and this increase was suppressed by resveratrol; the suppressive effect of resveratrol was greatly repressed by Compound C which is an inhibitor of AMPK. Collectively, these data suggest that resveratrol blocks T0901317-induced lipid accumulation in the liver and can be considered for inclusion into the treatment of diseases involving activation of liver X receptor.
PMID: 23591747
Dosing info:
Three groups of mice (n = 5 for each group) were used, including the carrier solution-treated control group, T0901317-treated group (5 mg/kg, i.p.), and the group with combined treatment with T0901317 (5 mg/kg,i.p.) and resveratrol (200 mg/kg, p.o.). The mice were treated daily for 5 days.
